Sepsis immunopathology: Perspectives of monitoring and modulation of the immune disturbances

Archivum Immunologiae et Therapiae Experimentalis

Volumn 60, Issue 2, 2012, Pages 123-135

  Skirecki, Tomasz ^a   Borkowska Zielińska, Urszula ^a   Złotorowicz, Małgorzata ^a   Hoser, Grazyna ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Flow cytometry; Immunomodulation; Monitoring; Sepsis

Indexed keywords

CLARITHROMYCIN; CYTOKINE; DROTRECOGIN; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MACROLIDE; METHYLPREDNISOLONE; PLACEBO; PROCALCITONIN; TUMOR NECROSIS FACTOR;

ANTIMICROBIAL ACTIVITY; AUTOIMMUNE DISEASE; CAUSE OF DEATH; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE PRODUCTION; DRUG MECHANISM; HEMOFILTRATION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOPATHOLOGY; INTENSIVE CARE UNIT; LYMPHOCYTE FUNCTION; MONOCYTE; NEUTROPHIL; PATHOGENESIS; PATIENT MONITORING; PHAGOCYTOSIS; REVIEW; SECONDARY INFECTION; SEPSIS; T LYMPHOCYTE;

CLINICAL TRIALS AS TOPIC; CYTOKINES; GLUCOCORTICOIDS; HEPARIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; MACROLIDES; MONITORING, IMMUNOLOGIC; SEPSIS;

EID: 84858698598     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-012-0166-1     Document Type: Review

References (132)

1. Adib-Conquy M, Cavaillon JM (2009) Compensatory anti-inflammatory response syndrome. Thromb Haemost 101:36-47
2. Almog YM, Shefer AM, Novack VM et al (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880-885
3. Almog Y, Novack V, Eisinger M et al (2007) The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 35:372-378 (Pubitemid 46148524)
4. Ando H, Takamura T, Ota T et al (2000) Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294:1043-1046 (Pubitemid 30666857)
5. Angus DC, Linde-Zwirble WT (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310 (Pubitemid 32641789)
6. Annane D, Sébille V, Charpentier C et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862-871 (erratum in JAMA 2008; 300:1652)
7. Arnaud C, Burger F, Steffens S et al (2005) Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct anti-inflammatory effects of statins. Arterioscler Thromb Vasc Biol 25:1231-1236 (Pubitemid 40776614)
8. Baenkler M, Leykauf M, Johj S (2006) Functional analysis of eicosanoids from white blood cells in sepsis and SIRS. J Physiol Pharmacol 57(Suppl 12):25-33 (Pubitemid 46569826)
9. Balog A, Ocsovszki I, Ma?ndi Y (2002) Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes. Immunol Lett 84:199-203 (Pubitemid 35292379)
10. Bandyopadhyay G, De A, Laudanski K et al (2007) Negative signaling contributes to T-cell anergy in trauma patients. Crit Care Med 35:794-801 (Pubitemid 46407793)
11. Becker KL, Nylén ES, White JC et al (2004) Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 89:1512-1525
12. Bernard GR, Ely EW, Wright TJ et al (2001a) Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29:2051-2059 (Pubitemid 33063531)
13. Bernard GR, Vincent JL, Laterre PF et al (2001b) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709 (Pubitemid 32204987)
14. Bilbault P, Lavaux T, Launoy A et al (2007) Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. Crit Care Med 35:69-75 (Pubitemid 46035679)
15. Bo L, Wang F, Zhu J et al (2011) Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care 15:R58
16. Bone RC (1996) Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24:1125-1128
17. Bone RC, Balk RA, Cerra FB et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655
18. Bouadma L, Luyt CE, Tubach F et al (2010) Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463-474
19. Castellanos-Ortega A, Suberviola B, García-Astudillo LA et al (2010) Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: results of a three-year follow-up quasi-experimental study. Crit Care Med 38:1036-1043
20. Cavaillon JM, Adib-Conquy M (2007) Determining the degree of immunodysregulation in sepsis. Contrib Nephrol 156:101-111
21. Christou NV, Meakins JL, Gordon J et al (1995) The delayed hypersensitivity response and host resistance in surgical patients. 20 years later. Ann Surg 222:534-546
22. Cole L, Bellomo R, Journois D et al (2001) High-volume haemofiltration in human septic shock. Intensive Care Med 27:978-986 (Pubitemid 32662478)
23. Cornet AD, Smit EG, Beishuizen A et al (2007) The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 98:579-586 (Pubitemid 47412883)
24. Cortellare M, Cofrancesco E, Arbustini E et al (2002) Atorvastatin and thrombogeneicity of the carotid atherosclerotic plaque: the ATROCAP study. Throm Haemost 88:41-47 (Pubitemid 34752265)
25. Cummings CJ, Martin TR, Frevert CW et al (1999) Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J Immunol 162:2341-2346 (Pubitemid 29288860)
26. Dahaba AA, Hagara B, Fall A et al (2006) Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 97:503-508 (Pubitemid 44419965)
27. Dandona P, Nix D, Wilson MF et al (1994) Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79:1605-1608
28. Danikas D, Karakantza M, Theodorou G et al (2008) Prognostic value of phagocytic activity of neutrophils and monocytes in sepsis. Correlation to CD64 and CD14 antigen expression. Clin Exp Immunol 154:87-97
29. Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296-327
30. Demartini G, Esposti D, Marthyn P et al (2004) Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community acquired pneumonia. J Chemother 16:82-85 (Pubitemid 38519737)
31. Di Carlo JV, Alexander SR (2005) Hemofiltration for cytokine-driven illness: the mediator delivery hypothesis. Int J Artif Organs 28:777-786 (Pubitemid 41535720)
32. Döcke WD, Randow F, Syrbe U et al (1997) Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 6:678-681 (Pubitemid 27264980)
33. Döcke WD, Höflich C, Davis KA et al (2005) Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 51:2341-2347 (Pubitemid 41692579)
34. Donnino MW, Cocchi MN, Howell MN et al (2007) Statin therapy in patients with sepsis. Acad Emerg Med 16:230-234
35. Draisma A, Dorresteijn M, Pickkers P et al (2008) The effect of systemic iNOS inhibition during human endotoxemia on the development of tolerance to different TLR-stimuli. Innate Immun 14:153-159
36. Dries DJ, Jurkovich GJ, Maier RV et al (1994) Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch Surg 129:1031-1041
37. Elphick GF, Sarangi PP, Hyun YM et al (2009) Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 113:4078-4085
38. Feistritzer C, Schuepbach RA, Mosnier LO et al (2006) Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem 281:20077-20084 (Pubitemid 44065782)
39. Fioretto JR, Martin JG, Kurokawa CS et al (2008) Interleukin-6 and procalcitonin in children with sepsis and septic shock. Cytokine 43:160-164
40. Fuchs TA, Abed U, Goosmann C et al (2007) Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 176:231-241 (Pubitemid 46143263)
41. Galley HF, El Sakka NE, Webster NR et al (2008) Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions. Br J Anaesth 100:815-819 (Pubitemid 351774323)
42. Gao F, Linhartowa L, Jahnston AM et al (2008) Statins and sepsis. Br J Anaesth 100:288-298 (Pubitemid 351773654)
43. Giamarellos-Bourboulis EJ, Routsi C, Plachouras D et al (2006) Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock? Crit Care 10:R76
44. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C et al (2008) Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 46:1157-1164 (Pubitemid 351589897)
45. Gogos C, Kotsaki A, Pelekanou A et al (2010) Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care 14:R96
46. Gonzalez-Rey E, Chorny A, Delgado M (2007) Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 7:52-63 (Pubitemid 46020827)
47. Granowitz EV, Porat R, Mier JW et al (1993) Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol 151:1637-1645 (Pubitemid 23219302)
48. Greineder CF, Nelson PW, Dressel AL et al (2007) In vitro and in silico analysis of annexin V binding to lymphocytes as a biomarker in emergency department sepsis studies. Acad Emerg Med 14:763-771 (Pubitemid 47268176)
49. Harbarth S, Holeckova K, Froidevaux C, Geneva Sepsis Network et al (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164:396-402 (Pubitemid 32778205)
50. Hochreiter M, Köhler T, Schweiger AM et al (2009) Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 13:R83
51. Hodder RV, Hall R, Russell JA et al (2009) Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort. Crit Care 13:R78
52. Holub M, Klucková Z, Helcl M et al (2003) Lymphocyte subset numbers depend on the bacterial origin of sepsis. Clin Microbiol Infect 9:202-211 (Pubitemid 36511679)
53. Honore PM, Jamez J, Wauthier M et al (2000) Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 28:3581-3587
54. Honoré PM, Joannes-Boyau O, Gressens B (2007) Blood and plasma treatments: the rationale of high-volume hemofiltration. Contrib Nephrol 156:387-395
55. Honoré PM, Joannes-Boyau O, Collin V et al (2009) Continuous hemofiltration in 2009: what is new for clinicians regarding pathophysiology, preferred technique and recommended dose? Blood Purif 28:135-143
56. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Eng J Med 348:138-150 (Pubitemid 36056721)
57. Hotchkiss RS, Tinsley KW, Swanson PE et al (2001) Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166:6952-6963 (Pubitemid 32467243)
58. Hustinx WN, van Kessel CP, Heezius E et al (1998) Effects of granulocyte colony-stimulating factor (G-CSF) treatment on granulocyte function and receptor expression in patients with ventilator-dependent pneumonia. Clin Exp Immunol 112:334-340 (Pubitemid 28266695)
59. Jaimes F, De La Rosa G, Morales C et al (2009) Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 37:1185-1196
60. Janda S, Young A, Fitzgerald JM et al (2010) The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 25:656.e7-e22
61. Jensen JU, Lundgren B, Hein L et al (2008) The Procalcitonin and Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker procalcitonin and pro-active diagnostic and therapeutic responses to abnormal procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. BMC Infect Dis 8:91
62. Jensen JU, Hein L, Lundgren B et al (2011) Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 39:2048-2058
63. Jiang H, Chess L (2004) An integrated model of immunoregulation mediated by regulatory T cell subsets. Adv Immunol 83:253-288 (Pubitemid 38657643)
64. Joyce DE, Nelson DR, Grinnell BW (2004) Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway. Crit Care Med 32(5 Suppl):S280-S286
65. Kettelhack C, Hohenberger P, Schulze G et al (2000) Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med 28:1040-1046 (Pubitemid 30262075)
66. Kikuchi T, Hagiwara K, Honda Y et al (2002) Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-κB transcription factors. J Antimicrob Chemother 49:745-755 (Pubitemid 34537634)
67. Kreymann KG, de Heer G, Nierhaus A et al (2007) Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 35:2677-2685 (Pubitemid 350175761)
68. Krysiak R, Okopien B, Herman ZS (2003) Effects of HMG-CaA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 63:1821-1854 (Pubitemid 37083030)
69. Laufs U, La Fata V, Plutzky J et al (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-11235
70. Le Tulzo Y, Pangault C, Amiot L et al (2004) Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med 169:1144-1151 (Pubitemid 38624795)
71. Lederer JA, Rodrick ML, Mannick JA (1999) The effects of injury on the adaptive immune response. Shock 11:153-159
72. Levy MM, Dellinger PR, Townsend SR et al (2010) The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 36:222-231
73. Llevadot J, Murasawa S, Kureishi Y et al (2001) HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108:399-405 (Pubitemid 32730786)
74. Maddur MS, Othy S, Hegde P et al (2010) Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol 30(Suppl 1):S4-S8
75. Marie C, Muret J, Fitting C et al (1998) Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. Blood 91:3439-3446 (Pubitemid 28193897)
76. Meynaar IA, Droog W, Batstra M et al (2011) In critically III patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract 2011:594645
77. Monneret G, Pachot A, Laroche B et al (2000) Procalcitonin and calcitonin gene-related peptide decrease LPS-induced TNF production by human circulating blood cells. Cytokine 12:762-764 (Pubitemid 30453513)
78. Monneret G, Debard AL, Venet F et al (2003) Marked elevation of human circulating CD4+ CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 31:2068-2071 (Pubitemid 36900766)
79. Monneret G, Finck ME, Venet F et al (2004) The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 95:193-198 (Pubitemid 39237665)
80. Monneret G, Lepape A, Voirin N et al (2006) Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 32:1175-1178
81. Monneret G, Voirin N, Krawice-Radanne I et al (2007) Soluble human leukocyte antigen-G5 in septic shock: marked and persisting elevation as a predictor of survival. Crit Care Med 35:1942-1947 (Pubitemid 47220370)
82. Monneret G, Venet F, Pachot A et al (2008) Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 14:64-78 (Pubitemid 351356886)
83. Monneret G, Venet F, Meisel C et al (2010) Assessment of monocytic HLA-DR expression in ICU patients: analytical issues for multicentric flow cytometry studies. Crit Care 14:432
84. Monserrat J, de Pablo R, Reyes E et al (2009) Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients. Crit Care 13:R26
85. Mullard A (2011) Drug withdrawal sends critical care specialists back to basics. Lancet 378:1769
86. Munoz C, Carlet J, Fitting C et al (1991) Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:1747-1754
87. Negi VS, Elluru S, Sibéril S et al (2007) Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 27:233-245 (Pubitemid 46790823)
88. Neyrinck AP, Liu KD, Howard JP et al (2009) Protective mechanisms of activated protein C in severe inflammatory disorders. Br J Pharmacol 158:1034-1047
89. Nobre V, Harbarth S, Graf JD et al (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177:498-505 (Pubitemid 351442188)
90. Oberholzer A, Oberholzer C, Moldawer LL (2002) Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 30(1 Suppl):S58-S63 (Pubitemid 34131163)
91. Oberholzer A, Souza SM, Tschoeke SK et al (2005) Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 23:488-493 (Pubitemid 40677419)
92. Okajima K (2001) Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 184:258-274
93. Opal SM, Fisher CJ, Dhainaut JF et al (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind placebo-controlled, multicenter trial. Crit Care Med 25:1115-1124 (Pubitemid 27310249)
94. Peng Z, Pai P, Han-Min W et al (2010) Evaluation of the effects of pulse high-volume hemofiltration in patients with severe sepsis: a preliminary study. Int J Artif Organs 33:505-511
95. Ploder M, Pelinka L, Schmuckenschlager C et al (2006) Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 25:129-134
96. Presneill JJ, Harris T, Stewart AG et al (2002) A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 166:138-143 (Pubitemid 34765447)
97. Ramachandran R, Hollenberg MD (2008) Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 153(Suppl 1):S263-S282 (Pubitemid 351340983)
98. Reinhart K, Menges T, Gardlund B et al (2001) Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES Study. Crit Care Med 29: 765-769 (Pubitemid 32299714)
99. Restrepo MI, Mortensen EM, Waterer GW et al (2009) Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 33:153-159
100. Ridker PM, Rifai N, Pfeffer MA et al (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230-235 (Pubitemid 29340127)
101. Ronco C, Bellomo R, Homel P et al (2000) Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356:26-30 (Pubitemid 30416991)
102. Ronco C, Ricci Z, Bellomo R (2002) Importance of increased ultrafiltration volume and impact on mortality: sepsis and cytokine story and the role for CVVH. EDTNA ERCA J Suppl 2:13-18
103. Ronco C, Tetta C, Mariano F et al (2003) Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 27:792-801 (Pubitemid 37108619)
104. Rosenbloom AJ, Linden PK, Dorrance A et al (2005) Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 127:2139-2150
105. Schefold JC, Hasper D, von Haehling S et al (2008) Interleukin-6 serum level assessment using a new qualitative point-of-care test in sepsis: a comparison with ELISA measurements. Clin Biochem 41:893-898
106. Schiff DE, Rae J, Martin TR et al (1997) Increases phagocyte CD64 expression and improved Fc-receptor mediated phagocytosis following in vivo recombinant human interferon-γ treatment of normal healthy subjects. Blood 90:3187-3194 (Pubitemid 27444215)
107. Schroeder S, Hochreiter M, Koehler T et al (2009) Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 394:221-226
108. Schultz MJ (2005) Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchitis and cystic fibrosis. J Antimicrob Chemother 54:21-28
109. Slofstra SH, ten Cate H, Spek CA (2006) Signal transduction induced by activated protein C: no role in protection against sepsis? Trends Mol Med 12:374-381 (Pubitemid 44149239)
110. Sprung CL, Annane D, Keh D, CORTICUS Study Group et al (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111-124
111. Stephend DP, Thomas JH, Higgins A et al (2008) Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor on patients with septic shock. Crit Care Med 36:448-454 (Pubitemid 351158618)
112. Stocker M, Hop WC, van Rossum AM (2010) Effect of procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: a multi-centre randomized superiority and non-inferiority intervention study. BMC Pediatr 10:89
113. Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A et al (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33:564-573 (Pubitemid 40365558)
114. Taccone FS, Stordeur P, De Backer D et al (2009) Gamma-globulin levels in patients with community-acquired septic shock. Shock 32:379-385
115. Taneja R, Sharma AP, Hallett MB et al (2008) Immature circulating neutrophils in sepsis have impaired phagocytosis and calcium signaling. Shock 30:618-622
116. Tang BM, Eslick GD, Craig JC et al (2007) Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7:210-217 (Pubitemid 46274517)
117. Terblanche MJ, Pinto R, Whiteley C et al (2001) Statins do not prevent acute organ failure in ventilated ICU patients: singlecentre retrospective cohort study. Crit Care 15:R74
118. Torgersen C, Moser P, Luckner G et al (2009) Macroscopic postmortem findings in 235 surgical intensive care patients. Anesth Analg 108:1841-1847
119. Townsend SR, Schorr C, Levy MM (2008) Reducing mortality in severe sepsis: the Surviving Sepsis Campaign. Clin Chest Med 29:721-733
120. Tracey KJ (2007) Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 117:289-296
121. Turgeon AF, Hutton B, Fergusson DA et al (2007) Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 146:193-203 (Pubitemid 351650633)
122. Venet F, Pachot A, Debard AL et al (2004) Increased percentage of CD4+ CD25+ regulatory T cells during septic shock is due to the decrease of CD4+ CD25- lymphocytes. Crit Care Med 32:2329-2331 (Pubitemid 39491817)
123. Venet F, Bohé J, Debard AL et al (2005) Both percentage of gammadelta T lymphocytes and CD3 expression are reduced during septic shock. Crit Care Med 33:2836-2840 (Pubitemid 41816419)
124. Venet F, Chung CS, Monneret G et al (2008) Regulatory T cell populations in sepsis and trauma. J Leukoc Biol 83:523-535 (Pubitemid 351966861)
125. Waage A, Brandtzaeg P, Halstensen A et al (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 169:333-338 (Pubitemid 19035565)
126. Wallace PK, Keler T, Coleman K et al (1997) Humanized mab H22 binds the human high affinity Fc receptor for IgG(FcgammaR1), blocks phagocytosis and modulates receptor expression. J Leukoc Biol 62:469-479 (Pubitemid 27459776)
127. Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251 (Pubitemid 29329996)
128. Werdan K, Pilz G, Bujdoso O, Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group et al (2007) Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 35:2693-2701 (Pubitemid 350175763)
129. Williams AC, Galley HF, Watt AM et al (2005) Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother 56:502-506 (Pubitemid 41264127)
130. Yasuda H, Yuen PS, Hu X et al (2006) Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int 69:1535-1542
131. Zeerleder S, Hack CE, Wuillemin WA (2005) Disseminated intravascular coagulation in sepsis. Chest 128:2864-2875 (Pubitemid 41507648)
132. Zeng W, Matter WF, Yan SB et al (2004) Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med 32(5 Suppl):S302-S308